Walder Wyss has acted as Swiss counsel to CRISPR
CRISPR Therapeutics announced subsequent sales under the Open Market Sale AgreementSM with Jefferies LLC (Jefferies), under which CRISPR may offer and sell, from time to time at its sole discretion through Jefferies (as its sales agent), common shares having an aggregate offering price of up to USD 350 million. The sales will be made by any method that is deemed an “at the market offering” (ATM) under the US Securities Act.